Polymer microsphere inks for semi-solid extrusion 3D printing at ambient conditions.

Autor: Pohjola J; Biotechnology, Department of Life Technologies, Faculty of Technology, University of Turku, FI-20014 Turku, Finland; Pharmaceutical Sciences, Bayer Oy, FI-20210 Turku, Finland. Electronic address: juuso.pohjola1@bayer.com., Jokinen M; DelSiTech, FI-20520 Turku, Finland., Soukka T; Biotechnology, Department of Life Technologies, Faculty of Technology, University of Turku, FI-20014 Turku, Finland., Stolt M; Pharmaceutical Sciences, Bayer Oy, FI-20210 Turku, Finland.
Jazyk: angličtina
Zdroj: Journal of the mechanical behavior of biomedical materials [J Mech Behav Biomed Mater] 2024 Dec; Vol. 160, pp. 106783. Date of Electronic Publication: 2024 Oct 16.
DOI: 10.1016/j.jmbbm.2024.106783
Abstrakt: Extrusion-based 3D printing methods have great potential for manufacturing of personalized polymer-based drug-releasing systems. However, traditional melt-based extrusion techniques are often unsuitable for processing thermally labile molecules. Consequently, methods that utilize the extrusion of semi-solid inks under mild conditions are frequently employed. The rheological properties of the semi-solid inks have a substantial impact on the 3D printability, making it necessary to evaluate and tailor these properties. Here, we report a novel semi-solid extrusion 3D printing method based on utilization of a Carbopol gel matrix containing various concentrations of polymeric microspheres. We also demonstrate the use of a solvent vapor-based post-processing method for enhancing the mechanical strength of the printed objects. As our approach enables room-temperature processing of polymers typically used in the pharmaceutical industry, it may also facilitate the broader application of 3D printing and microsphere technologies in preparation of personalized medicine.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Juuso Pohjola reports equipment, drugs, or supplies was provided by Bayer Oy. Juuso Pohjola reports a relationship with Bayer Oy that includes: employment. Mikael Stolt reports a relationship with Bayer Oy that includes: employment. Mika Jokinen reports a relationship with DelSiTech Ltd that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: